Accunome Biotechnology Co., Limited (“Accunome” ) was founded in Xiuzhou National High-Tech Park（Jiaxing, Zhejiang）in July 2018, and has set up wholly-owned R&D subsidiaries in San Diego (USA) and Shanghai with full capabilities of R&D and manufacturing for both instruments and reagents in IVD industry.

As an innovation driven company in the health care industry, Accunome has launched its first sample-to-answer molecular diagnostics platform DXcellence System with a broad menu of tests for critical diseases.

Accunome has received National Class Ill Registration Certificate from China NMPA for DXcellence System. It also obtained CE mark in Europe for DXcellence System and tests（respiratory infections, etc).

Accunome is committed to providing innovative tools in life sciences and diagnostics industries. The company has built a 2000 square meter GMP plant in Jiaxing and has completed ISO13485 certification. Accunome will continue to develop products and solutions to meet the market demand and assist physicians in managing patient care and serving public health worldwide.